Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.54 |
| ▸ | CNR2 | P34972 | 6/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.54 |
| ▸ | CCR1 | P32246 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758879 | 0.91 | MAPT (0.52) | CNR1CNR2ELANEHPGDLMNA | |
| SCHEMBL5759081 | 0.90 | CNR1 (0.55) | CNR1CNR2ELANECCR1HPGD | |
| SCHEMBL5756279 | 0.89 | CNR1 (0.54) | CNR1CNR2ELANECCR1HPGD | |
| SCHEMBL5756974 | 0.86 | ELANE (0.62) | CNR1CNR2ELANECCR1HPGD | |
| SCHEMBL5757041 | 0.84 | ELANE (0.52) | CNR1CNR2ELANECCR1HPGD | |
| SCHEMBL5756619 | 0.84 | ELANE (0.60) | CNR1CNR2ELANECCR1HPGD | |
| SCHEMBL5756437 | 0.83 | ELANE (0.56) | CNR1CNR2ELANECCR1HPGD | |
| SCHEMBL5758889 | 0.83 | CNR1 (0.50) | CNR1CNR2ELANECCR1HPGD | |
| SCHEMBL5756834 | 0.82 | ELANE (0.78) | CNR1CNR2ELANECCR1HPGD | |
| SCHEMBL5759883 | 0.82 | ELANE (0.58) | CNR1CNR2ELANECCR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | CNR1 2232/4885CNR2 2164/4885ELANE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.